INVESTOR ALERT: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law

Core Viewpoint - Soleno Therapeutics Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to undisclosed safety concerns regarding its product DCCR, which is intended for treating hyperphagia in Prader-Willi syndrome patients [1]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled "City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc." and covers investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025 [1]. - Investors have until May 5, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Soleno and its executives failed to disclose significant safety concerns related to DCCR, including issues of excess fluid retention in clinical trial participants [1]. Group 2: Allegations and Impact - The lawsuit claims that the Phase 3 clinical trial program for DCCR misrepresented safety evidence, leading to greater risks than disclosed [1]. - Following a critical report by Scorpion Capital on August 15, 2025, Soleno's stock price fell nearly 12% over two trading days [1]. - After a patient death was reported on September 10, 2025, the stock price declined approximately 19% over two trading days [1]. - On November 4, 2025, Soleno reported a disruption in DCCR's launch trajectory, resulting in a further 27% decline in stock price [1]. Group 3: Company Background - Soleno Therapeutics is a biopharmaceutical company focused on developing therapeutics for rare diseases, with DCCR as its only commercial product [1]. - The company is currently facing significant challenges regarding the commercial viability of DCCR due to the allegations and subsequent stock price declines [1].